MAPT and Alzheimer disease: Although p‐tau181 has shown very good performance as an AD biomarker (Karikari et al, 2020, 2021; Thijssen et al, 2020; Janelidze et al, 2020a; Grothe et al, 2021), multiple (plasma and CSF) studies support that p‐tau217 may be a more useful biomarker than p‐tau181, as it has stronger correlations with amyloid and tau pathology proxies, earlier change, and better diagnostic accuracy (Barthélemy et al, 2020; Hanes et al, 2020; Palmqvist et al, 2020; Janelidze et al, 2020b, 2021a; Grothe et al, 2021; Leuzy et al, 2021).